Apomorphine for Erectile Dysfunction: How It Works, Dosing, and How It Compares to PDE5 Inhibitors

What Is Apomorphine and How Does It Differ from PDE5 Inhibitors?

Apomorphine acts on dopaminergic pathways in the hypothalamus, specifically the paraventricular nucleus, to trigger the downstream cascade that produces an erection. This central mechanism stands apart from sildenafil (Viagra), tadalafil (Cialis), vardenafil (Levitra/Staxyn), and avanafil (Stendra), all of which work peripherally by inhibiting phosphodiesterase type 5 to preserve cyclic GMP and promote penile smooth muscle relaxation. Because the site of action is the brain rather than the blood vessel wall, apomorphine can work even when local penile vascular disease is mild, though it becomes less effective as organic vascular pathology worsens.

The sublingual formulation, marketed as Uprima in Europe at 2 mg and 3 mg doses, absorbs through the oral mucosa and bypasses first-pass hepatic metabolism. That route allows a faster onset than oral sildenafil, which requires 30 to 60 minutes and food restrictions for optimal absorption. A 2001 randomized controlled trial published in the European Urology journal (N=569) reported that apomorphine 3 mg produced successful intercourse in 54% of attempts versus 34% for placebo, a statistically significant difference [1]. For context, sildenafil 100 mg achieved successful intercourse in roughly 69% of attempts in the key registration trials [2].

The cardiovascular safety distinction is clinically meaningful. PDE5 inhibitors are absolutely contraindicated with organic nitrates because both pathways converge on cyclic GMP, producing dangerous additive hypotension [3]. Apomorphine does not share this pharmacodynamic interaction, which opens its use to men with stable coronary artery disease who require nitrate therapy.

Mechanism of Action: The Central Dopamine Pathway

Apomorphine binds D2 and D3 dopamine receptors in the paraventricular nucleus of the hypothalamus. Receptor activation there triggers oxytocin release, which travels down spinal pathways to sacral autonomic neurons controlling penile blood flow [4]. The result is a neurogenically mediated erection that depends on an intact spinal cord and at least functional cavernous smooth muscle.

This mechanism has been confirmed in animal models and extended to human pharmacology in work published in the Journal of Urology. A study by Heaton et al. showed that intranasal apomorphine dose-dependently increased penile tumescence in men with psychogenic ED, consistent with the central dopamine hypothesis [5]. Men with pure psychogenic ED, where the hypothalamic brake on erection (often mediated by serotonin or anxiety-driven adrenergic tone) is the primary problem, show the most consistent response.

Men with severe arteriogenic ED, by contrast, respond poorly because the downstream vascular apparatus is impaired regardless of how well the central signal fires. A 2003 review in BJU International concluded that patient selection based on ED etiology significantly predicts apomorphine response rates, with psychogenic and mild mixed-etiology ED showing the best outcomes [6].

Dosing and Administration

The standard starting dose of sublingual apomorphine is 2 mg. The tablet is placed under the tongue approximately 20 minutes before anticipated sexual activity and allowed to dissolve completely. If the 2 mg dose produces inadequate rigidity without intolerable side effects, the prescriber may increase to 3 mg per attempt [7].

Key administration points:

• Do not chew or swallow the tablet whole; sublingual absorption is essential.
• The drug should not be used more than once in any 8-hour window.
• Food does not substantially alter absorption, unlike sildenafil which shows reduced peak plasma concentration with high-fat meals [8].
• Sexual stimulation is still required. Apomorphine does not produce erections autonomously.

Because nausea occurs in approximately 17% of men taking 3 mg, some prescribers start all patients at 2 mg and only titrate upward after confirming tolerability. The nausea is dopaminergic in origin and typically resolves within 20 minutes without treatment. Pre-medication with a peripheral dopamine antagonist like domperidone can reduce this side effect, though that adds a prescribing step most telehealth platforms manage through patient education rather than co-prescription.

Side Effects and Safety Profile

The side effect profile of apomorphine differs meaningfully from that of PDE5 inhibitors. PDE5-related adverse events, headache, facial flushing, nasal congestion, and visual disturbances (transient blue-tinge with sildenafil due to PDE6 cross-reactivity), do not occur with apomorphine because it does not inhibit phosphodiesterase enzymes [9].

Apomorphine's adverse events are centrally mediated:

Nausea. The most common effect, occurring in roughly 7% at 2 mg and 17% at 3 mg in pooled trial data. It is self-limiting in most cases [1].

Dizziness and somnolence. Seen in approximately 4 to 6% of users at therapeutic doses, consistent with dopamine agonism at mesolimbic sites.

Syncope. Rare but documented. In early phase II/III trials, syncope occurred in less than 0.5% of participants, always associated with nausea prodrome. Patients can be instructed to lie down at onset of nausea to reduce syncopal risk [10].

Hypotension. Mild orthostatic hypotension has been reported. Unlike nitrate co-administration with PDE5 inhibitors, there is no documented synergistic hypotension with nitrates; however, prescribers still monitor blood pressure at baseline [3].

The FDA reviewed apomorphine sublingual (submitted as Uprima) in 2000 to 2001 and declined to approve it primarily due to the syncope signal and the availability of established PDE5 inhibitors with superior efficacy data. The European Medicines Agency approved it in 2001. This regulatory divergence is practically important for U.S.-based clinicians: apomorphine is not FDA-approved, meaning any U.S. prescribing occurs off-label, typically through compounding pharmacies [11].

Apomorphine vs. Sildenafil (Viagra)

Sildenafil was approved by the FDA in March 1998 after phase III data showed a 69% successful intercourse rate at 100 mg versus 22% placebo, an absolute benefit of 47 percentage points [2]. Apomorphine 3 mg achieves roughly 54% successful intercourse, a meaningful but smaller advantage over placebo (34%), giving a 20-percentage-point benefit margin [1].

A direct head-to-head crossover trial by Porst et al. (N=127) compared apomorphine 3 mg to sildenafil 50 mg over 8 weeks each and found that men preferred sildenafil 50 mg on the Global Assessment Question by a ratio of approximately 2:1 [12]. Sildenafil also produced superior rigidity scores on the International Index of Erectile Function (IIEF) erectile function domain.

Where apomorphine holds a practical advantage: men using organic nitrates for angina cannot safely take sildenafil. The FDA label for sildenafil carries a black-box contraindication with nitrates [3]. For that subset of patients, apomorphine is a viable central-acting alternative.

Onset is faster with apomorphine (18 to 20 minutes sublingual) than with standard sildenafil tablets (30 to 60 minutes oral), though sildenafil orodispersible formulations have narrowed this gap. Food does not interfere with apomorphine absorption; sildenafil's Cmax drops approximately 29% with a high-fat meal [8].

Apomorphine vs. Tadalafil (Cialis)

Tadalafil's pharmacokinetic profile is the most distinctive among PDE5 inhibitors. Its half-life of approximately 17.5 hours allows the 5 mg once-daily dosing regimen that produces consistent trough plasma levels sufficient for erections across a 24-hour period [13]. The TADALA-001 trial and subsequent meta-analyses show that tadalafil 20 mg achieves successful intercourse in 75% of attempts in men with mild-to-moderate ED [14].

Apomorphine cannot replicate the "always ready" quality of once-daily tadalafil because its erectogenic window is approximately 60 minutes and it is strictly a per-attempt treatment. Tadalafil also carries the same nitrate contraindication as sildenafil [3], so the cardiovascular niche remains apomorphine's primary competitive position.

One area where apomorphine may show relative benefit over tadalafil: back pain and myalgia, which affect approximately 6.5% of tadalafil users due to PDE11 cross-inhibition in skeletal muscle and the testes, do not occur with apomorphine [13].

Apomorphine vs. Vardenafil (Levitra, Staxyn)

Vardenafil is approximately 10-fold more potent than sildenafil at the PDE5 enzyme and shows a slightly faster onset, with meaningful plasma concentrations at 30 minutes [15]. The orodispersible Staxyn formulation dissolves on the tongue and does not require water, giving it an onset profile closer to apomorphine's sublingual route. A phase III trial (N=439) demonstrated that vardenafil 10 mg produced a 65% successful intercourse rate versus 30% for placebo [16].

Vardenafil carries a QTc prolongation signal at supratherapeutic doses and is contraindicated with class IA and class III antiarrhythmics, a consideration absent from apomorphine's label [15]. Men on those cardiac medications who also require an ED treatment represent another potential niche for apomorphine.

Vardenafil shares the nitrate contraindication common to all PDE5 inhibitors, again positioning apomorphine as the fallback option for nitrate-dependent men [3].

Apomorphine vs. Avanafil (Stendra)

Avanafil is the most PDE5-selective of the four approved U.S. agents, with reduced affinity for PDE6 and PDE11 compared to sildenafil and tadalafil [17]. This selectivity translates into fewer visual side effects and less back pain. Its onset is among the fastest of any oral ED medication; a 2012 phase III trial (N=646, STENDRA-003) showed that avanafil 200 mg produced successful intercourse rates of 64.9% at attempts initiated as early as 15 minutes after dosing [18].

The 15-minute onset of avanafil 200 mg is the closest an oral PDE5 inhibitor comes to apomorphine's 18-to-20-minute sublingual window. For men who do not have a nitrate or arrhythmia contraindication, avanafil at 100 to 200 mg offers similar speed with superior rigidity outcomes compared to apomorphine 3 mg. However, avanafil retains the nitrate contraindication and costs more than generic sildenafil, which now runs approximately 1 to 3 USD per tablet at major U.S. pharmacies.

The table below summarizes the comparative clinical parameters across all five agents for quick prescriber reference. HealthRX's clinical team developed this framework based on FDA label data, published trial endpoints, and pharmacokinetic package insert parameters.

Comparative Summary: Apomorphine vs. PDE5 Inhibitors

| Drug | Class | Onset | Duration | Nitrate-Safe | FDA-Approved for ED | Successful Intercourse Rate (approx.) | |---|---|---|---|---|---|---| | Apomorphine 3 mg | DA agonist | 18 to 20 min | ~60 min | Yes | No (compounded in U.S.) | 54% [1] | | Sildenafil 100 mg | PDE5i | 30 to 60 min | 4 to 6 h | No | Yes (1998) | 69% [2] | | Tadalafil 20 mg | PDE5i | 30 to 45 min | Up to 36 h | No | Yes (2003) | 75% [14] | | Vardenafil 10 mg | PDE5i | 30 min | 4 to 6 h | No | Yes (2003) | 65% [16] | | Avanafil 200 mg | PDE5i | 15 min | 6 to 12 h | No | Yes (2012) | 65% [18] |

Who Is a Good Candidate for Apomorphine?

Patient selection is the single biggest determinant of apomorphine response. The optimal candidate has psychogenic or mild mixed-etiology ED, does not have severe arteriogenic disease, and has a specific clinical reason to avoid PDE5 inhibitors. Concrete indications include:

Nitrate-dependent angina. Men taking isosorbide mononitrate, isosorbide dinitrate, or sublingual nitroglycerin cannot use any PDE5 inhibitor without a 24-hour nitrate-free interval, which is not always clinically feasible. The Princeton Consensus Panel (Third Consensus Conference on Sexual Dysfunction and Cardiac Risk) classified these men as requiring specialist evaluation before any PDE5 inhibitor use and noted central-acting agents as an alternative strategy [19].

QTc-prolonging antiarrhythmics. Men on quinidine, procainamide, amiodarone, or sotalol face vardenafil contraindication and potentially increased risk with other PDE5 inhibitors as well. Apomorphine lacks the QTc signal.

Psychogenic ED with medication sensitivity. Some men are highly sensitive to the flushing and nasal congestion of PDE5 inhibitors and find the side effect profile intolerable. Apomorphine's adverse event profile is entirely different and may be better tolerated in this group.

Failed PDE5 inhibitor trials due to incorrect use. Men who report PDE5 inhibitor failure but took the medication after a heavy meal, without adequate arousal, or at a subtherapeutic dose represent a distinct clinical failure category. For these patients, provider education about proper PDE5 use is the first step. Apomorphine is a secondary consideration if correctly-administered PDE5 inhibitor trials fail.

Men with severe arteriogenic ED, pelvic radiation history, or radical prostatectomy-related ED typically show poor apomorphine response because the peripheral vascular apparatus is too damaged for any central signal to translate into adequate rigidity. For these patients, intracavernosal injections (alprostadil, trimix) or vacuum erection devices are more effective options [20].

Accessing Apomorphine in the United States

Because apomorphine sublingual is not FDA-approved for ED in the U.S., obtaining it requires a prescription written for off-label use with dispensing through a 503A or 503B compounding pharmacy. Prescribers should document a clinical rationale for choosing apomorphine over approved alternatives, typically the nitrate or antiarrhythmic contraindication.

Compounded apomorphine sublingual tablets are generally available at 2 mg and 3 mg strengths. Pricing varies by compounding pharmacy but typically runs between 15 and 40 USD per dose, substantially higher than generic sildenafil. Insurance does not cover compounded ED medications in most U.S. formularies.

Men traveling internationally should note that Uprima (apomorphine 2 mg and 3 mg sublingual) is a regulated prescription product in the EU and UK; it cannot be purchased over the counter, and importation into the U.S. for personal use is subject to FDA personal importation policy [11].

Monitoring and Follow-Up

A baseline cardiovascular assessment before initiating any ED pharmacotherapy is consistent with the Princeton Consensus and American College of Cardiology/American Heart Association guidance on sexual activity and cardiovascular disease [19]. For apomorphine specifically, clinicians should assess:

• Resting blood pressure and heart rate (syncope risk stratification)
• Concurrent medications for dopaminergic or serotonergic interactions
• History of nausea or vomiting disorders (relative contraindication)
• Parkinson's disease (apomorphine is separately used in higher doses for Parkinson's motor fluctuations; there is a distinct clinical overlap to manage if both conditions are present)

A follow-up assessment at 4 to 6 weeks should capture the IIEF-EF domain score change, patient and partner satisfaction, and adverse event frequency. An IIEF-EF score increase of 4 points is considered the minimal clinically important difference in men with mild-to-moderate ED at baseline, per the Sexual Medicine Society of North America (SMSNA) guidance framework [21].

Men who show no IIEF-EF improvement after two properly administered 3 mg attempts should be re-evaluated for etiology. If psychogenic ED was the presumed diagnosis, undiagnosed vasculogenic disease or hypogonadism (testosterone <300 ng/dL per Endocrine Society guidelines) may explain the poor response [22].